Health Headlines: Proton therapy expands to treat eye cancer
BOSTON, Mass. (Ivanhoe Newswire) – When you hear “melanoma,” you probably think skin cancer, since melanoma is a type of cancer that develops in the cells that produce melanin, the pigment that gives skin its color. But our eyes also have these melanin-producing cells and can develop melanoma. Now, some of the top centers in the U.S. are using the power of protons to kill the cancer and save the eye.
It might not be visible to the untrained eye, but your ophthalmologist might uncover a spot or freckle that could be a sign of ocular melanoma, cancer of the eye.
“Ocular melanoma, historically, was treated by enucleation, meaning the removal of the eye,” says Mass. General Cancer Center radiation oncologist, Helen Shih, MD, who has expertise in proton therapy.
But for some patients, that may no longer be the case.
Traditional radiation delivers X-rays to the tumor but the radiation can go beyond the tumor and damage healthy tissue. Proton therapy delivered radiation delivers a beam of protons that stops at the tumor.
Dr. Shih explains, “We typically go through the white of the eye, which is fairly resistant to the radiation. It treats the tumor and the beam stops there. So, there’s no radiation or virtually no radiation delivered to the brain.”
Dr. Shih says it’s important to catch ocular cancer early before it spreads. When treated early, proton therapy can cure almost 95 percent of ocular cancers.
“I would say the overwhelming majority of people that we treat, granted they are selected carefully, they do not only save their eye, but frequently we save their vision,” Dr. Shih emphasizes.
While proton therapy has been used for years for the treatment of other cancers, like brain cancer, breast cancer, and lung cancer, Dr. Shih says there are only a handful of hospitals and academic institutions across the U.S. using proton therapy for ocular melanoma.
Contributors to this news report include Cyndy McGrath, Producer; Kirk Manson, Videographer; Roque Correa, Editor.
Copyright 2023 KPLC. All rights reserved.